Orphazyme appoints Kim Stratton as Chief Executive Officer

Jul 15, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company’s Board of Directors has appointed Kim Stratton as the new Chief Executive Officer of Orphazyme, succeeding Anders Hinsby. Kim Stratton will take up her new position on October 1, 2019.

Orphazyme appoints Kim Stratton as chief executive

Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)

Jul 7, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has received constructive advice from the European Medicines Agency (EMA)’s Scientific Advice Working Group in response to the request for advice submitted to the agency. After receiving this feedback, Orphazyme confirms its intention to file the MAA for NPC in the first half of 2020.

Orphazyme to prepare for filing of arimoclomol in EU

Major shareholder announcement

May 31, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of May 29, 2019 holds a total 998,072 shares in the Company, corresponding to 4.99% of the share capital and that Danske Bank as of May 29, 2019 controls 7.74% of the voting rights in the Company.

Major shareholder announcement

Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled

Apr 23, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that its Phase II/III trial of arimoclomol for the treatment of sporadic Inclusion Body Myositis (sIBM) is fully enrolled. Performance of interim analysis and study completion expected in H1 2020 and by end 2020, respectively. Results are expected in H1 2021.

Orphazymes phase II & III trial in sporadic inclusion

Major shareholder announcement

Apr 17, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of April 16, 2019 holds a total 1,000,395 shares in the Company, corresponding to 5.00% of the share capital and 7.69% of the voting rights in the Company.

Major shareholder announcement

Share capital and voting rights in Orphazyme A/S

Mar 29, 2019

Following a share capital increase in Orphazyme A/S (ticker: ORPHA.CO), CVR no. 32266355 (“Orphazyme”) in March 2019, the total nominal share capital of Orphazyme is DKK 19,984,799, divided into 19,984,799 shares each with a nominal value of DKK 1. Each share carries one vote at Orphazyme’s general meetings and accordingly the total number of voting rights in Orphazyme is 19,984,799.

Share capital and voting rights in Orphazyme as

Resolution passed at the Annual General Meeting

Mar 27, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today held its Annual General Meeting, at which the Annual General Meeting.

Resolutions passed at the annual general meeting

Orphazyme to present at Cowen & Co Annual Health Care Conference

Mar 11, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the Cowen & Co Annual Health Care Conference in Boston, MA, USA on March 12, 2019.

Orphazyme to present at cowen co annual health care

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Mar 8, 2019

Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.

Reporting of transactions in Orphazymes shares

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Mar 7, 2019

Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.

Reporting of transactions in Orphazymes shares

Selskabsmeddelelser